Skip to main content
SpringerLink
Log in

High-dose cyclophosphamide for autoimmunity and alloimmunity

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6:638–47.

    Article  CAS  PubMed  Google Scholar 

  2. Duester G. Genetic dissection of retinoid dehydrogenases. Chem Biol Interact. 2001;130–132(1–3):469–80.

    Article  PubMed  Google Scholar 

  3. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res. 1984;44:5156–60.

    CAS  PubMed  Google Scholar 

  4. Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood. 1990;75:1947–50.

    CAS  PubMed  Google Scholar 

  5. Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995;85:2742–6.

    CAS  PubMed  Google Scholar 

  6. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 2005;365:1647–56.

    Article  CAS  PubMed  Google Scholar 

  7. Thomas ED, Storb R, Fefer A, Slichter SJ, Bryant JI, Buckner CD, et al. Aplastic anaemia treated by marrow transplantation. Lancet. 1972;1:284–9.

    CAS  PubMed  Google Scholar 

  8. Thomas ED, Storb R, Giblett ER, Longpre B, Weiden PL, Fefer A, et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol. 1976;4:97–102.

    CAS  PubMed  Google Scholar 

  9. Sensenbrenner LL, Steele AA, Santos GW. Recovery of hematologic competence without engraftment following attempted bone marrow transplantation for aplastic anemia: report of a case with diffusion chamber studies. Exp Hematol. 1977;77:51–8.

    Google Scholar 

  10. Baran DT, Griner PF, Klemperer MR. Recovery from aplastic anemia after treatment with cyclophosphamide. N Engl J Med. 1976;295:1522–3.

    Article  CAS  PubMed  Google Scholar 

  11. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in acquired severe aplastic anemia following high-dose cyclophosphamide. Blood. 1996;87:491–4.

    CAS  PubMed  Google Scholar 

  12. Brodsky RA, Sensenbrenner LL, Smith BD, Dorr D, Seaman PJ, Karp JE, et al. Durable treatment-free remission following high-dose cyclophosphamide for previously untreated severe aplastic anemia. Ann Intern Med. 2001;135:477–83.

    CAS  PubMed  Google Scholar 

  13. Tisdale JF, Dunn DE, Geller N, Plante M, Nunez O, Dunbar CE, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 2000;356:1554–9.

    Article  CAS  PubMed  Google Scholar 

  14. Savage WJ, DeRusso PA, Resar LM, Chen AR, Higman MA, Loeb DM, et al. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer. 2007;49:947–51.

    Article  PubMed  Google Scholar 

  15. Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Am J Hematol. 2001;66:71.

    Article  CAS  PubMed  Google Scholar 

  16. Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol. 2004;32:435–40.

    Article  CAS  PubMed  Google Scholar 

  17. Brodsky RA, Chen A, Dorr D, Fuchs EJ, Huff CA, Luznik L, Smith BD, Matsui WH, Goodman SN, Ambinder RF et al. High dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2009 [Epub ahead of print].

  18. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol. 2005;141:1–9.

    Article  CAS  PubMed  Google Scholar 

  19. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum. 2006;54:3750–60.

    Article  PubMed  Google Scholar 

  20. Brodsky RA, Jones RJ. Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages. Autoimmunity. 2008;41(8):596–600.

    Article  CAS  PubMed  Google Scholar 

  21. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006;295:527–35.

    Article  CAS  PubMed  Google Scholar 

  22. Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 2002;100:704–6.

    Article  CAS  PubMed  Google Scholar 

  23. Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol. 2006;63:1388–93.

    Article  PubMed  Google Scholar 

  24. Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008;65:1044–51.

    Article  PubMed  Google Scholar 

  25. Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease. Ann Intern Med. 1998;129:1031–5.

    CAS  PubMed  Google Scholar 

  26. Brannagan TH III, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology. 2002;58:1856–8.

    CAS  PubMed  Google Scholar 

  27. Tehlirian CV, Hummers LK, White B, Brodsky RA, Wigley FM. High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis. 2008;67:775–81.

    Article  CAS  PubMed  Google Scholar 

  28. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: “Rebooting” with high-dose cyclophosphamide. Ann Neurol. 2003;53:29–34.

    Article  CAS  PubMed  Google Scholar 

  29. Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci. 2008;1132:305–14.

    Article  CAS  PubMed  Google Scholar 

  30. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 2003;48:166–73.

    Article  CAS  PubMed  Google Scholar 

  31. Dussan KB, Magder L, Brodsky RA, Jones RJ, Petri M. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17:1079–85.

    Article  CAS  PubMed  Google Scholar 

  32. Oliva-Hemker MM, Loeb DM, Abraham SC, Lederman HM. Remission of severe autoimmune enteropathy after treatment with high-dose cyclophosphamide. J Pediatr Gastroenterol Nutr. 2003;36:639–43.

    Article  PubMed  Google Scholar 

  33. Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology. 1996;195:129.

    CAS  PubMed  Google Scholar 

  34. O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.

    Article  PubMed  Google Scholar 

  35. Brodsky RA, Fuller AK, Ratner LE, Leffell MS, Jones RJ. Elimination of alloantibodies by immunoablative high-dose cyclophosphamide. Transplantation. 2001;71:482–4.

    Article  CAS  PubMed  Google Scholar 

  36. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.

    Article  CAS  PubMed  Google Scholar 

  37. Bolanos-Meade J, Brodsky RA. Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Curr Opin Oncol. 2009;21:158–61.

    Article  PubMed  Google Scholar 

  38. Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008;42:523–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Supported in part by National Institutes of Health Grants CA70970. Under a licensing agreement between Accentia Pharmaceuticals and the Johns Hopkins University, Dr. Brodsky is entitled to a share of royalty received by the University on sales of a method of administering high-dose cyclophosphamide. The study described in this article could impact the value of this method of administering the drug. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

Author information

Authors and Affiliations

  1. The Division of Hematology, Johns Hopkins University School of Medicine, Ross Research Building, 720 Rutland Avenue, Baltimore, MD, 21205, USA

    Robert A. Brodsky

Authors
  1. Robert A. Brodsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert A. Brodsky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brodsky, R.A. High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunol Res 47, 179–184 (2010). https://doi.org/10.1007/s12026-009-8149-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-009-8149-y

Keywords

Search

Navigation